Method of screening for drug hypersensitivity reaction

a drug hypersensitivity and reaction technology, applied in biochemistry apparatus and processes, organic chemistry, sugar derivatives, etc., can solve the problems of severe morbidity and mortality, prolong survival, and reduce the risk of hiv-1 infection complications, so as to increase the risk and increase the incidence of a hypersensitivity reaction

Active Publication Date: 2007-06-28
VIIV HEALTHCARE UK LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] A further aspect of the present invention is a method of screening a human subject as an aid in predicting the subject's risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir, by genotyping a sample of DNA from the subject to determine the presence of a polymorphism in the TNFα gene, where the polymorphism has previously been associated with an increased risk of abacavir HSR compared to the risk of HSR associated with alternate TNFα polymorphisms. Detecting the presence of a TNFα genotype that has been associated with an increased incidence of hypersensitivity reaction to abacavir (compared to the incidence of abacavir HSR associated with other TNFα genotypes) indicates that the subject is at an increased risk of a hypersensitivity reaction to abacavir.
[0013] A further aspect of the present invention is a method of screening a human subject as an aid in predicting the subject's risk of experiencing a hypersensitivity reaction to a therapeutic regime of abacavir, by genotyping a sample of DNA from the subject to determine the presence of a polymorphism in an HLA gene, where the polymorphism has previously been associated with an increased risk of abacavir HSR compared to the risk of HSR associated with alternate polymorphisms. The presence of an HLA genotype that has been associated with an increased incidence of hypersensitivity reaction to abacavir (compared to the incidence of abacavir HSR associated with other HLA genotypes) indicates that the subject is at an increased risk of a hypersensitivity reaction to abacavir.

Problems solved by technology

Therapy with combinations of antiretroviral agents can prolong survival and decrease the risk of complications of HIV-1 infection.
Adverse reactions may occur with any antiretroviral agent, some with the potential to cause severe morbidity and mortality.
Continued administration of abacavir in the face of an ongoing reaction or reinstitution of abacavir in patients with a prior history of a reaction may result in a sudden, severe, and potentially fatal reaction.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of screening for drug hypersensitivity reaction
  • Method of screening for drug hypersensitivity reaction

Examples

Experimental program
Comparison scheme
Effect test

example 1

Study Design

[0083] A retrospective, case-control study was conducted with adult (>18 years of age) HIV-infected subjects who participated in a Glaxo Wellcome abacavir clinical development program. Subjects were classified as either “case” or “control” subjects based on the following. Case subjects had experienced an episode of suspected or confirmed hypersensitivity to abacavir; control subjects had received Abacavir for at least six weeks, but had not experienced an episode of confirmed or suspected HSR. The six-week treatment period was chosen based on the knowledge that the majority of HSR events occur within the first six weeks of treatment. Case narratives were collected at or close to the time of the suspected or confirmed hypersensitivity reaction. Control subjects were matched for study (if possible) ethnicity, gender, CD4+cell count (if available; four CD4+ ranges: 500 cells / mm3); and age (plus or minus 5 years). Wherever possible, treatment regime was also matched (“naive...

example 2

Screening TNFα

[0089] The presence of the TNFα G(-237A) polymorphism may be determined using a fluorescent dye and quenching agent-based PCR assay, such as the allele discrimination form of the 5′ nuclease assay (Lee and Bloch, Nucleic Acids Research 21:3761 (1993)). In brief, this assay uses two allele specific probes labeled differentially with fluorescent “reporter” dyes at the 5′ ends and with a common quenching agent at the 3′ ends. Normally the fluorescence of each reporter dye is quenched by the quenching agent when present in the same oligonucleotide molecule. The allele specific probes are used in conjunction with two primers, one of which hybridizes to the template 5′ of allele specific probes while the other hybridizes to the template 3′ of the such probes.

[0090] The presence of the TNFα G(-237)A polymorphisms was determined by the method of allelic discrimination using the 5′-nuclease assay. Two allele specific probes labeled with a different fluorescent dye at the 5′ en...

example 3

Screening HLA-B57

[0097] Genotyping of the HLA-B gene was performed in samples from 120 subjects (44 Cases and 76 Controls) in the research laboratories of the Anthony Nolan Bone Marrow Trust (Royal Free Hospital, London, UK). Typing was primarily conducted using Reference Strand-mediated Conformation Analysis (RSCA; see, e.g., Pel-Freez® Clinical Systems, LLC) as is known in the art. Arguello et al., Reviews in Immunogenetics, 1:209 (1999); Arguello et al., Tissue Antigens, 52:57 (1998). DNA sequencing and Sequence Specific Oligonucleotide Probe (SSOP) techniques (see, e.g., Yoshida et al., Hum Immunol 34:257 (1992); Smith et al., Hum Immunol 55:74 (1997)) were used when necessary as backup techniques to determine HLA genotype.

[0098] Of the Cases, 25 / 44 (57%) were found to have the HLA-B57 allele present (i.e., were either heterozygous or homozygous for the HLA-B57 allele), whereas only 3 / 76 (4%) of the Controls were found to have the HLA-B57 allele present (each was heterozygous ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
polymorphicaaaaaaaaaa
min-widthaaaaaaaaaa
Login to view more

Abstract

Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority from U.S. Provisional Application No. 60 / 314,026 filed Aug. 21, 2001 and U.S. Provisional Application No. 60 / 336,850 filed Oct. 30, 2001.BACKGROUND [0002] Hypersensitivity reactions (HSR) are unexpected, immune (allergy)-like reactions that occur in a minority of patients treated with antiretroviral therapy. No single symptom or laboratory test has been found to predict or diagnose such events. Common symptoms, which appear in combinations, include fever, rash, gastrointestinal reactions, severe fatigue, and respiratory symptoms. Such hypersensitivity reactions constitute a distinct clinical entity and are not the simple rashes (mild rashes without systemic symptoms) that are common reactions to many drugs. Hypersensitivity reactions resolve on discontinuation of the causative drug, but return on reinitiation. The exact mechanism of hypersensitivity reactions is unknown. [0003] Antiretroviral therapy has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68
CPCC12Q1/6876C12Q2600/156A61P31/18
Inventor HETHERINGTON, SETHHUGHES, ARLENE R.LAI, ERIC H.MOSTELLER, MICHAEL JR.SHORTINO, DENISE D.
Owner VIIV HEALTHCARE UK LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap